About us

NuCapCure is on a mission to revolutionise modern oncology with two breakthrough therapies for the world's most common but incurable brain tumour, Glioblastoma multiforme (GBM), to advance the wellbeing of global society.

GBM is the most frequent and deadliest brain tumour, diagnosed in almost a quarter of a million people worldwide every year. The current standard treatment – a combination of surgery, radiotherapy and chemotherapy – only prolongs patients' lives by about a year and places a significant physical and financial burden on those affected and on global healthcare systems.

The seven NuCapCure partner institutions from the fields of physics, chemistry and biology are working on two radical, multimodal cancer treatments based on protons and neutrons that are specifically tailored to GBM. The therapeutic approaches are designed to exploit the tumour's own cellular biosynthesis and transform cancer cells into a kind of intracellular mini-chemistry laboratory, forcing them to produce drugs. The new treatments are intended to protect the surrounding healthy brain tissue and are also significantly more cost-effective than conservative tumour therapies currently used, especially when the chances of a cure are taken into account.